Literature DB >> 23997543

D2 plus radical resection combined with perioperative chemotherapy for advanced gastric cancer with pyloric obstruction.

Yian Du1, Xiangdong Cheng, Zhiyuan Xu, Litao Yang, Ling Huang, Bing Wang, Pengfei Yu, Ruizeng Dong.   

Abstract

A patient with advanced gastric cancer complicated with pyloric obstruction was treated using D2 + radical resection combined with perioperative chemotherapy, and had satisfying outcomes. The perioperative chemotherapy regimen was Taxol and S1 (tegafur, gimeracil, and oteracil). Three cycles of neoadjuvant chemotherapy were delivered before surgery, and three cycles of adjuvant therapy after surgery. PR was achieved after chemotherapy. D2 + dissection of stations 8p, 12b, 12p, 13 and 14v lymph nodes was performed on September 10, 2012.

Entities:  

Keywords:  Advanced gastric cancer; D2 + lymph node dissection; perioperative chemotherapy; pyloric obstruction

Year:  2013        PMID： 23997543      PMCID： PMC3752345          DOI： 10.3978/j.issn.1000-9604.2013.08.17

Source DB:  PubMed          Journal:  Chin J Cancer Res        ISSN： 1000-9604            Impact factor:   5.087


  6 in total

1.  Role of the extended lymphadenectomy in gastric cancer surgery: experience in a single institution.

Authors:  Alejandro Sierra; Fernando M Regueira; José L Hernández-Lizoáin; Fernando Pardo; Miguel A Martínez-Gonzalez; Javier A-Cienfuegos
Journal:  Ann Surg Oncol       Date:  2003-04       Impact factor: 5.344

2.  Outcome of distal gastric cancer with pyloric stenosis after curative resection.

Authors:  J-H Chen; C-W Wu; S-S Lo; A F-Y Li; M-C Hsieh; K-H Shen; W-Y Lui
Journal:  Eur J Surg Oncol       Date:  2007-02-27       Impact factor: 4.424

Review 3.  Gastric cancer: D2 dissection or low Maruyama Index-based surgery--a debate.

Authors:  Harold O Douglass; Scott A Hundahl; John S Macdonald; Vijay P Khatri
Journal:  Surg Oncol Clin N Am       Date:  2007-01       Impact factor: 3.495

4.  A 10-year experience with Japanese-type radical lymph node dissection for gastric cancer outside of Japan.

Authors:  G R Jatzko; P H Lisborg; H Denk; M Klimpfinger; H M Stettner
Journal:  Cancer       Date:  1995-10-15       Impact factor: 6.860

5.  Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Authors:  David Cunningham; Naureen Starling; Sheela Rao; Timothy Iveson; Marianne Nicolson; Fareeda Coxon; Gary Middleton; Francis Daniel; Jacqueline Oates; Andrew Richard Norman
Journal:  N Engl J Med       Date:  2008-01-03       Impact factor: 91.245

6.  Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.

Authors:  Y-K Kang; W-K Kang; D-B Shin; J Chen; J Xiong; J Wang; M Lichinitser; Z Guan; R Khasanov; L Zheng; M Philco-Salas; T Suarez; J Santamaria; G Forster; P I McCloud
Journal:  Ann Oncol       Date:  2009-01-19       Impact factor: 32.976
  6 in total
  3 in total

1.  Investigation of the potential role of preoperative chemotherapy in treatment for gastric cancer with outlet obstruction.

Authors:  Xuelong Jiao; Yanbing Zhou
Journal:  Mol Clin Oncol       Date:  2015-06-24

2.  Comparison of D2 and D2 plus radical surgery for advanced distal gastric cancer: a randomized controlled study.

Authors:  Pengfei Yu; Yian Du; Zhiyuan Xu; Ling Huang; Xiangdong Cheng
Journal:  World J Surg Oncol       Date:  2019-02-06       Impact factor: 2.754

3.  Evaluation of D2-plus radical resection for gastric cancer with pyloric invasion.

Authors:  Zhi-Yuan Xu; Can Hu; Shangqi Chen; Yi-An Du; Ling Huang; Peng-Fei Yu; Li-Jing Wang; Xiang-Dong Cheng
Journal:  BMC Surg       Date:  2019-11-20       Impact factor: 2.102
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.